<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Balsalazide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Balsalazide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Balsalazide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11139" href="/d/html/11139.html" rel="external">see "Balsalazide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13082" href="/d/html/13082.html" rel="external">see "Balsalazide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F139019"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Colazal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F139034"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        5-Aminosalicylic Acid Derivative;</li>
<li>
                        Anti-inflammatory Agent</li></ul></div>
<div class="block doa drugH1Div" id="F139021"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3504104-5393-4688-8e87-33480a9459f0">Ulcerative colitis, mildly to moderately active</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, mildly to moderately active (alternative agent):</b>
<b>Note: </b>Alternative monotherapy for induction of remission for distal disease, <b>or</b> in combination with topical agents for induction of remission for left-sided/extensive disease or refractory distal disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction of remission: </b>
<b>Note: </b>Alternative monotherapy for induction of remission for distal disease, <b>or</b> in combination with topical agents for induction of remission for left-sided/extensive disease or refractory distal disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30576644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30576644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2.25 g 3 times daily for 8 to 12 weeks, followed by maintenance dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of remission (off-label use):</b>
<b>Oral:</b> 1.5 or 3 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9882028','lexi-content-ref-11709512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9882028','lexi-content-ref-11709512'])">Ref</a></span>). Some experts use 2.25 to 6.75 g/day in three divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AlHashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AlHashash.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991969"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment prior to treatment initiation: </i>There are no dosage adjustments provided in the manufacturer's labeling. Renal toxicity has been observed with other 5-aminosalicylic acid products; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment during treatment: </i>Discontinue use if kidney function deteriorates during treatment.</p></div>
<div class="block doha drugH1Div" id="F50989320"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; evaluate risk versus benefit in patients with preexisting impairment.</p></div>
<div class="block doe drugH1Div" id="F139022"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F4005150"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13082" href="/d/html/13082.html" rel="external">see "Balsalazide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Capsules: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">2.25 g (three 750 mg capsules) 3 times daily (total daily dose: 6.75 g/<b>day</b>) for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>or </b></p>
<p style="text-indent:-2em;margin-left:6em;">750 mg (one capsule) 3 times daily (total daily dose: 2.25 g/<b>day</b>) for up to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> A multicenter, double-blind clinical trial in pediatric patients (n=68, ages 5 to 17 years) showed clinical improvement in both treatment groups (2.25 g/<b>day</b> and 6.75 g/<b>day</b>); there was not a statistical difference in clinical response between the two treatment groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19633577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19633577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Capsules: Oral: 2.25 g (three 750 mg capsules) 3 times daily (total daily dose: 6.75 g/<b>day</b>) for up to 12 weeks.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51073384"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment prior to treatment initiation: </i>There are no dosage adjustments provided in the manufacturer's labeling. Renal toxicity has been observed with other 5-aminosalicylic acid products; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Kidney impairment during treatment: </i>Discontinue use if kidney function deteriorates during treatment.</p></div>
<div class="block dohp drugH1Div" id="F51073385"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; evaluate risk versus benefit in patients with preexisting impairment.</p></div>
<div class="block adr drugH1Div" id="F138995"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (6% to 12%), diarrhea (5% to 11%), upper abdominal pain (children and adolescents: 9% to 17%), vomiting (children and adolescents: 3% to 17%; adults: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (8% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 11%; adults: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps (adults: 1%), anorexia (adults: 2%), constipation (adults: 1%), dyspepsia (adults: 2%), flatulence (adults: 2%), hematochezia (children and adolescents: 9%), nausea (5% to 9%), stomatitis (children and adolescents: 6%), xerostomia (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (children and adolescents: 6%), urinary tract infection (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (children and adolescents: 3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (children and adolescents: 3% to 6%; adults: 2%), insomnia (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (adults: 4%), myalgia (adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children and adolescents: 6%; adults: 2%), flu-like symptoms (adults: 1%), nasopharyngitis (children and adolescents: 3% to 9%), pharyngitis (adults: 2%), pharyngolaryngeal pain (children and adolescents: 6%), respiratory tract infection (adults: 4%), rhinitis (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Kawasaki-like syndrome, myocarditis, pericarditis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, alopecia, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic cirrhosis, hepatic failure, hepatic injury (hepatocellular), hepatic necrosis, hepatotoxicity, increased liver enzymes, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis, kidney failure, nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion, pleurisy, pneumonia (with and without eosinophilia), pulmonary alveolitis</p></div>
<div class="block coi drugH1Div" id="F139006"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to balsalazide or its metabolites, aminosalicylates, salicylates, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F138993"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous adverse reactions, including acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported. If a reaction occurs, discontinue immediately and consider further evaluation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Mesalamine-induced hypersensitivity reactions have been reported and may include internal organ involvement, such as hepatitis, myocarditis, pericarditis, nephritis, hematologic abnormalities, and/or pneumonitis. Monitor for signs and symptoms of hypersensitivity; discontinue treatment if hypersensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intolerance syndrome: May cause an acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea; sometimes fever, headache, rash); may be hard to discern from an exacerbation; monitor for worsening of symptoms, and discontinue immediately if syndrome occurs or is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Use with caution in patients with preexisting skin conditions (including atopic dermatitis and atopic eczema); severe photosensitivity reactions have been reported. Use skin protection (protective clothing and broad-spectrum sunscreen) and avoid prolonged exposure to sunlight and ultraviolet light.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Renal impairment (including minimal change disease, acute and chronic interstitial nephritis, and renal failure) has been reported. A renal function evaluation is recommended prior to initiation of therapy and periodically during treatment. Evaluate risk versus benefit in patients with renal impairment, history of renal disease, or concurrently taking nephrotoxic medications. Cases of nephrolithiasis (including stones with 100% mesalamine content) have occurred with mesalamine use. Stones may be radiotransparent and undetectable by standard imaging. Ensure patients are adequately hydrated during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Staining: May cause staining of teeth or tongue if capsule is opened and sprinkled on food.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfasalazine hypersensitivity: Patients with hypersensitivity to sulfasalazine may react to mesalamine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI tract obstruction: Avoid use in patients at risk for upper GI tract obstruction (eg, pyloric stenosis); may cause prolonged gastric retention and delay release of drug in the colon.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Evaluate risk versus benefit of therapy in patients with hepatic impairment; hepatic failure has been observed with other mesalamine (5-aminosalicylic acid) products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment, with a history of renal disease, or on nephrotoxic medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; uncontrolled studies and postmarketing reports suggest an increased incidence of blood dyscrasias (ie, agranulocytosis, neutropenia, pancytopenia) in patients &gt;65 years of age taking mesalamine-containing products.</p></div>
<div class="block foc drugH1Div" id="F139002"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as disodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Colazal: 750 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg</p></div>
<div class="block geq drugH1Div" id="F138989"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F139007"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Balsalazide Disodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Colazal Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $7.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F3347863"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May administer with or without food. Swallow capsule whole; do not cut, break, crush, or chew. May also be opened and sprinkled on ~10 mL of applesauce if patient cannot swallow whole; mix contents within the applesauce. Applesauce mixture may be chewed; swallow immediately, do not store mixture for later use. When sprinkled on food, may cause staining of teeth or tongue. Maintain adequate hydration during therapy (to minimize nephrolithiasis risk).</p></div>
<div class="block admp drugH1Div" id="F52612284"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food; administer with an adequate amount of fluid. Maintain adequate hydration during therapy (to minimize nephrolithiasis risk).</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Should be swallowed whole or may be opened and sprinkled on applesauce. Applesauce mixture may be chewed if necessary. The entire amount of applesauce mixture should be consumed immediately; do not store mixture for later use. When sprinkled on food, may cause staining of teeth or tongue. Color variation of powder inside capsule (ranging from orange to yellow) is expected.</p></div>
<div class="block use drugH1Div" id="F139003"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Ulcerative colitis, mildly to moderately active:</b> Treatment of mildly to moderately active ulcerative colitis in patients ≥5 years of age.</p></div>
<div class="block off-label drugH1Div" id="F50086274"><span class="drugH1">Use: Off-Label: Adult</span><p>Ulcerative colitis, mildly to moderately active, remission maintenance</p></div>
<div class="block mst drugH1Div" id="F139041"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Colazal may be confused with Clozaril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298812"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F138997"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Myelosuppressive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may enhance the myelosuppressive effect of Thiopurine Analogs. 5-Aminosalicylic Acid Derivatives may increase serum concentrations of the active metabolite(s) of Thiopurine Analogs. Specifically, exposure to the active 6-thioguanine nucleotides (6-TGN) may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.  Management: Avoid administration of salicylates for at least 6 weeks after adminstration of a varicella virus-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): 5-Aminosalicylic Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. 5-Aminosalicylic Acid Derivatives may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F139008"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Mesalamine (5-aminosalicylic acid) is the active metabolite of balsalazide; mesalamine is known to cross the placenta. Refer to the mesalamine monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F13316162"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if balsalazide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Mesalamine, 5-aminosalicylic acid, is the active metabolite of balsalazide. Mesalamine is present in breast milk; refer to the mesalamine monograph for additional information. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Breastfed infants should be monitored for diarrhea.</p></div>
<div class="block dic drugH1Div" id="F4005612"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F4005151"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (prior to and periodically during therapy); CBC (particularly in elderly patients); hepatic function; signs/symptoms of worsening acute intolerance syndrome or hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F138992"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Balsalazide is a prodrug, converted by bacterial azoreduction to 5-aminosalicylic acid (mesalamine, active), 4-aminobenzoyl-β-alanine (inert), and their metabolites. 5-aminosalicylic acid may decrease inflammation by blocking the production of arachidonic acid metabolites topically in the colon mucosa.</p></div>
<div class="block phk drugH1Div" id="F139005"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Very low and variable; in children, reported systemic absorption of balsalazide is increased compared to adults, but exposure to 5-ASA (active) is lower than adults (C<sub>max</sub>: 67% lower, AUC: 64% lower); time to steady state: ~2 weeks in pediatric and adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Balsalazide: ≥99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Azoreduced in the colon to 5-aminosalicylic acid (active), 4-aminobenzoyl-β-alanine (inert), and N-acetylated metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Primary effect is topical (colonic mucosa); therapeutic effect appears not to be influenced by the systemic half-life of balsalazide (1.9 hours) or its metabolites (5-ASA [9.5 hours], N-Ac-5-ASA [10.4 hours]).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Balsalazide: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (65% as 5-aminosalicylic acid, 4-aminobenzoyl-β-alanine, and N-acetylated metabolites); urine (&lt;16% as N-acetylated metabolites); Parent drug: Urine or feces (&lt;1%).</p></div>
<div class="block phksp drugH1Div" id="F51153965"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b> May have increased AUC.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539822"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Benoquin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao rui xi | Ao rui xin | Bei le si</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Premid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Colazide</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Colazide</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Balacol | Colorex | Cozabal | Intazide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Balzide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Colazal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Colazid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Balsalazide disodium | Colazal | Giazo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Colazid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Basazyde</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Garian</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AlHashash.1">
<a name="AlHashash.1"></a>Al Hashash J, Regueiro M. Medical management of low-risk adult patients with mild to moderate ulcerative colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colazal.1">
<a name="Colazal.1"></a>Colazal (balsalazide disodium) capsules [prescribing information]. Irvine, CA: LGM Pharma Solutions LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colazal.1">
<a name="Colazal.1"></a>Colazal (balsalazide disodium) capsules [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals, a division of Bausch Health US, LLC; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology</i>. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407188">
<a name="21407188"></a>Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2011;106(4):601-616. doi:10.1038/ajg.2011.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/21407188/pubmed" id="21407188" target="_blank">21407188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9882028">
<a name="9882028"></a>Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. <i>Aliment Pharmacol Ther</i>. 1998;12(12):1207-1216. doi:10.1046/j.1365-2036.1998.00427.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/9882028/pubmed" id="9882028" target="_blank">9882028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30576644">
<a name="30576644"></a>Ko CW, Singh S, Feuerstein JD, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. <i>Gastroenterology</i>. 2019;156(3):748-764. doi:10.1053/j.gastro.2018.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/30576644/pubmed" id="30576644" target="_blank">30576644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11709512">
<a name="11709512"></a>Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. <i>Gut</i>. 2001;49(6):783-789. doi:10.1136/gut.49.6.783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/11709512/pubmed" id="11709512" target="_blank">11709512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19633577">
<a name="19633577"></a>Quiros JA, Heyman MB, Pohl JF, et al. Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-Blind Study. <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(5):571-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/19633577/pubmed" id="19633577" target="_blank">19633577</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8713 Version 213.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
